A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19.
Reza Amani-BeniMohammad Kermani-AlghoraishiBahar DaroueiChristopher M ReidPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)
Post-discharge prophylaxis for COVID-19 patients is recommended after an individual assessment. The IMPROVE-DD model can help predict VTE risk. After distinguishing patients who need post-discharge AC therapy, DOACs for 30-35 days and LMWHs for 40-45 days can be the drug of choice. Further studies, particularly the results of the ongoing randomized controlled trials (RCTs), are required. Also, to properly handle such patients, every physician should consider lifestyle modification in addition to pharmacological treatment for post-discharge VTE prophylaxis.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- newly diagnosed
- ejection fraction
- metabolic syndrome
- cardiovascular disease
- sars cov
- type diabetes
- stem cells
- physical activity
- prognostic factors
- peritoneal dialysis
- mesenchymal stem cells
- clinical trial
- patient reported outcomes
- cell therapy
- electronic health record